Risk factors of disease activity in patients with Behçet’s syndrome
暂无分享,去创建一个
[1] A. Sarı,et al. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience. , 2019, Multiple sclerosis and related disorders.
[2] E. D’Amico,et al. The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis , 2019, Cells.
[3] A. Karadağ,et al. Behçet syndrome: A great imitator. , 2019, Clinics in dermatology.
[4] Guanfang Su,et al. Immunopathogenesis of Behcet's Disease , 2019, Front. Immunol..
[5] U. Pleyer,et al. Behçet-Syndrom , 2019, Gefässchirurgie.
[6] A. Mangoni,et al. Meta‐analysis of neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratio in rheumatoid arthritis , 2018, European journal of clinical investigation.
[7] Arash Salmaninejad,et al. Behçet’s disease: An immunogenetic perspective , 2018, Journal of cellular physiology.
[8] Y. Lee,et al. Neutrophil‐to‐lymphocyte ratio, mean platelet volume and platelet‐to‐lymphocyte ratio in Behçet’s disease and their correlation with disease activity: A meta‐analysis , 2018, International journal of rheumatic diseases.
[9] G. Hatemi,et al. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement. , 2018, Clinical and experimental rheumatology.
[10] M. Hammad,et al. Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in Behçet’s disease: which and when to use? , 2018, Clinical Rheumatology.
[11] N. Akkoç. Update on the epidemiology, risk factors and disease outcomes of Behçet's disease. , 2018, Best practice & research. Clinical rheumatology.
[12] Chang-Keun Lee,et al. Predicting eventual development of lupus nephritis at the time of diagnosis of systemic lupus erythematosus. , 2018, Seminars in arthritis and rheumatism.
[13] G. Hatemi,et al. Behçet syndrome: a contemporary view , 2018, Nature Reviews Rheumatology.
[14] G. Hatemi,et al. Biomarkers in vasculitis , 2018, Current opinion in rheumatology.
[15] C. Suh,et al. Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus , 2017, Clinical Rheumatology.
[16] S. Shenavandeh,et al. An elevated pro-inflammatory cytokines profile in Behcet's disease: A multiplex analysis. , 2017, Immunology letters.
[17] Ying Jiang,et al. Serum PLR and LMR in Behçet's disease , 2017, Medicine.
[18] F. Shahram,et al. Serum Profiles of Cytokines in Behcet’s Disease , 2017, Journal of clinical medicine.
[19] Yong-Beom Park,et al. Serum anti‐lysozyme is associated with disease activity of Behçet's disease , 2017, International journal of rheumatic diseases.
[20] F. Turkcu,et al. Novel markers of endothelial dysfunction and inflammation in Behçet’s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio , 2016, Clinical Rheumatology.
[21] G. Hatemi,et al. Ocular Involvement of Behçet’s Syndrome: a Comprehensive Review , 2015, Clinical Reviews in Allergy & Immunology.
[22] I. Olivieri,et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria , 2014 .
[23] Queiroz,et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] A. Tennant,et al. The Behçet's disease activity index. , 2003, Advances in experimental medicine and biology.
[25] A. Silman,et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. , 1999, Rheumatology.
[26] H. Yazıcı,et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. , 1984, Annals of the rheumatic diseases.
[27] E. Atra,et al. [Behcet's syndrome]. , 1968, Revista paulista de medicina.